adenocarcinoma is critical for therapy, but it is often
difficult to differentiate these tumors. Currently, there is no objective
standardized test to aid pathologists in differentiating between the many
possible tumors in the lung and pleura. Based on a few microRNA biomarkers
applying the Rosetta Genomics technology, this test is being developed to
separate mesothelioma from adenocarcinoma tumors including lung
adenocarcinoma and metastases to the lung or to the pleura. This test is
expected to be filed with the New York Department of Health in H2 2008.
- Cancer of Unknown Primary (CUP) - We continued to advance assay
development of microRNA-based test for cancer of unknown primary (CUP). The
test is being developed to distinguish among more than 20 possible tissues
of origin, and it is expected to be filed with the New York Department of
Health in H2 2008.
- Additional diagnostic tests - We continued the expansion of our
microRNA-based diagnostic pipeline with cancer-related indications and
indications related to women's health.
- Identified microRNAs that are potential biomarkers for differential
diagnosis of the following in lung cancer: primary vs. metastases,
neuroendocrine tumors vs.
- non-small cell lung cancer, lung cancer vs. thymoma, and carcinoid
vs. other neuroendocrine tumors.
- Identified specific microRNAs that are markers to differentiate
between primary liver and brain tumors and metastases to these organs.
- Women's health: Identified specific microRNAs that may be potential
markers for preeclampsia in serum. Demonstrated correlation between
microRNAs in serum and physiological conditions.
- Liver Cancer Therapeutic - Rosetta Genomics, in collaboration with
Isis Pharmaceuticals, Inc., has entered in vivo studies on antisense
oligonucleotide leads designed to inhibit a microRNA that it has identified
as a potential drug target.
Collaborations and Licensing
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1
. Rosetta Genomics Establishes Medical Advisory Board2
. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer3
. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 20084
. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma5
. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology6
. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer7
. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 20078
. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 20079
. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference10
. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference11
. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma